Related Experiment Videos
[18F FDG PET- applications in oncology].
I Răileanu1, V Rusu, C Stefănescu
1Facultatea de Medicină Disciplina de Biofizică şi Medicină Nucleară, Universitatea de Medicină şi Farmacie Gr. T. Popa Iaşi.
Summary
Positron Emission Tomography (PET) with 18F FDG offers advanced cancer diagnosis by highlighting unique glucose metabolism in tumor cells. This nuclear medicine technique aids in locating tumors, detecting metastasis, and monitoring treatment effectiveness.
Area of Science:
- Nuclear Medicine
- Oncology
- Medical Imaging
Background:
- 18F FDG-PET has evolved from studying cerebral metabolism to a crucial tool in oncology.
- Cancer cells exhibit altered glucose metabolism, making them detectable via 18F FDG-PET.
- This technique plays a significant role in modern cancer diagnosis and management.
Purpose of the Study:
- To synthesize information on 18F FDG-PET in cancer diagnosis and treatment monitoring.
- To detail the specifics of tumor cell glucose metabolism and PET technology.
- To review various cancer types identified using 18F FDG-PET.
Main Methods:
- Review of tumor cell glucose metabolism and PET functionality.
- Description of 18F FDG radiopharmaceutical synthesis and clinical procedures.
- Analysis of 18F FDG-PET applications in detecting and staging various cancers.
Main Results:
- 18F FDG-PET is effective in identifying unknown cancers, localizing tumors, and detecting metastasis.
- The technique is valuable for monitoring treatment response in oncology.
- Specific applications include diagnosis of lung, breast, lymphoma, melanoma, and colorectal cancers.
Conclusions:
- 18F FDG-PET is a pivotal advancement in nuclear medicine for oncological applications.
- The method's ability to visualize metabolic changes provides critical diagnostic and prognostic information.
- Clinical cases from CERMEP, Lyon, illustrate the broad utility of 18F FDG-PET in cancer management.